These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 15161675)

  • 21. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
    Bauer S; Duensing A; Demetri GD; Fletcher JA
    Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
    La Rosée P; Jia T; Demehri S; Härtel N; de Vries P; Bonham L; Hollenback D; Singer JW; Melo JV; Druker BJ; Deininger MW
    Clin Cancer Res; 2006 Nov; 12(21):6540-6. PubMed ID: 17085669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Guideline for chemotherapy of malignant lung cancer].
    Yamamoto N; Fukuoka M
    Gan To Kagaku Ryoho; 2002 Jun; 29(6):985-1007. PubMed ID: 12109452
    [No Abstract]   [Full Text] [Related]  

  • 24. [Attentive questions about treatment of chronic myelogenous leukemia with imatinib mesylate].
    Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):433-5. PubMed ID: 17147242
    [No Abstract]   [Full Text] [Related]  

  • 25. Topotecan for the treatment of small-cell lung cancer.
    Nicum SJ; O'Brien ME
    Expert Rev Anticancer Ther; 2007 Jun; 7(6):795-801. PubMed ID: 17555389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imatinib mesylate induces quiescence in gastrointestinal stromal tumor cells through the CDH1-SKP2-p27Kip1 signaling axis.
    Liu Y; Perdreau SA; Chatterjee P; Wang L; Kuan SF; Duensing A
    Cancer Res; 2008 Nov; 68(21):9015-23. PubMed ID: 18974147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer.
    Gridelli C; Rossi A; Maione P; Rossi E; Castaldo V; Sacco PC; Colantuoni G
    Oncologist; 2009 Jun; 14(6):612-20. PubMed ID: 19474164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor.
    Froehner M; Beuthien-Baumann B; Dittert DD; Schuler U; Wirth MP
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):716-8. PubMed ID: 16450163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
    Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can weight loss at presentation predict patient outcome in lung cancer?
    Temel J
    Nat Clin Pract Oncol; 2004 Dec; 1(2):68-9. PubMed ID: 16264819
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical and in vitro studies of imatinib in advanced carcinoid tumors.
    Yao JC; Zhang JX; Rashid A; Yeung SC; Szklaruk J; Hess K; Xie K; Ellis L; Abbruzzese JL; Ajani JA
    Clin Cancer Res; 2007 Jan; 13(1):234-40. PubMed ID: 17200360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imatinib as a paradigm of targeted therapies.
    Druker BJ
    Adv Cancer Res; 2004; 91():1-30. PubMed ID: 15327887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications.
    Roeder I; Horn M; Glauche I; Hochhaus A; Mueller MC; Loeffler M
    Nat Med; 2006 Oct; 12(10):1181-4. PubMed ID: 17013383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytogenetic characterisation and proteomic profiling of the Imatinib-resistant cell line KCL22-R.
    Rosenhahn J; Weise A; Michel S; Hennig K; Hartmann I; Schiefner J; Schubert K; Liehr T; von Eggeling F; Loncarevic IF
    Int J Oncol; 2007 Jul; 31(1):121-8. PubMed ID: 17549412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose cytarabine in small cell lung cancer.
    Osborne RJ; Clark PI; Slevin ML; Wrigley PF
    Cancer Treat Rep; 1987 Apr; 71(4):417-8. PubMed ID: 3030547
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines.
    Mitsiades CS; Sykoutri D; McMullan C; Poulaki V; Mitsiades N
    J Clin Endocrinol Metab; 2003 Oct; 88(10):5043-4; author reply 5044. PubMed ID: 14557495
    [No Abstract]   [Full Text] [Related]  

  • 37. New drugs in small cell lung cancer.
    Thatcher N
    Suppl Tumori; 2002; 1(4):S26-7. PubMed ID: 12415811
    [No Abstract]   [Full Text] [Related]  

  • 38. Warfarin for small-cell lung cancer: why not?
    Zacharski LR; Henderson WG
    J Clin Oncol; 1990 Jul; 8(7):1282-3. PubMed ID: 2162913
    [No Abstract]   [Full Text] [Related]  

  • 39. Quality of life in non-small-cell lung cancer.
    Hughes-Davies L; Billingham L; Cullen M
    J Clin Oncol; 2000 Apr; 18(8):1802. PubMed ID: 10764443
    [No Abstract]   [Full Text] [Related]  

  • 40. Maintenance chemotherapy for small cell lung cancer.
    Trillet-Lenoir V; Cucherat M; Gérard JP; Boissel JP
    Lung Cancer; 1998 Sep; 21(3):221-3, 225-6. PubMed ID: 9858000
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.